Biogen

#News: We announced that we have entered into a definitive agreement to acquire @ApellisPharma. This potential acquisition will bring two best-in-class commercialized immunology medicines to Biogen and accelerate our entry into nephrology. Read more: ow.ly/3PcZ50YB7Pp

#News: Today, the FDA approved a new dosing regimen option for our spinal muscular atrophy (SMA) therapy. This approval represents an important step toward expanding options for people living with SMA. Learn more: ow.ly/94tg50YAA9p

#News: At #AAD2026, we’re presenting new data for an investigational medicine for cutaneous lupus erythematosus (CLE), highlighting our ongoing efforts to advance a potential new option for people living with this serious form of lupus. Read more: ow.ly/c1tA50YA3J7

#News: Together with Eisai, we’re sharing new real-world data at #ADPD2026 evaluating long-term treatment persistence in the U.S. among people living with early Alzheimer’s disease. Read more: ow.ly/xbA650YwTRL

#News: Join us at the American Academy of Dermatology (AAD) Annual Meeting to learn about our late-breaking research for a potential cutaneous lupus erythematosus (CLE) treatment. Read more about the data we’re sharing at #AAD2026: ow.ly/bxpm50YwfPz

We’re heading to #ADPD2026 to discuss the latest research, clinical trials, and treatments for Alzheimer's disease (AD) and Parkinson's disease. Find us at Booth #2 to learn how we’re advancing research in this space. Learn more: ow.ly/HwZT50YuT70

Video description: Animated clip reading SMA News: Data and updates on an investigational treatment for SMA

#News: At the 2026 #MDAConference, hosted by @MDAorg, we’re presenting new Phase 1b results and details on the Phase 3 clinical development program for an investigational spinal muscular atrophy (SMA) medicine. Read more: ow.ly/g07g50YshGO

#News: We’re presenting new data and updates at the 2026 #MDAConference, hosted by @MDAorg, and #SMAEurope. Learn about the latest updates from our spinal muscular atrophy (SMA) pipeline: ow.ly/VRni50YpJBk

We look forward to sharing the latest progress in our ongoing systemic lupus erythematosus (SLE) research at #ELM2026 this week, hosted by @SLEuroSociety, alongside other industry experts, clinicians and researchers. Learn more about the event: sleuromeeting.eu

STARTING SOON: Join our Q4 and full year 2025 financial results live webcast at 8:30 AM ET. Join here: ow.ly/SxXw50Y9Exe #Earnings $BIIB

Today, we reported our Q4 and full year 2025 financial results which reflect our continued focus on strong execution and financial discipline. Read more: bit.ly/45NMnMi Forward-looking statements: biogen.com/forward-lookin… #Earnings $BIIB

#News: Data from a Phase 2/3 study for SMA has been published in @NatureMedicine, exploring the potential benefit for a broad range of people living with the disease. Read more: ow.ly/KK4a50Y8IjL

#News: The FDA granted Breakthrough Therapy Designation for an investigational medicine for cutaneous lupus erythematosus (CLE), marking a step forward in advancing a potential new option for people living with CLE. Read more: ow.ly/ObqP50Y4Mvf

#News: Today, the European Commission (EC) approved a new dosing option for people living with spinal muscular atrophy (SMA). Read more: ow.ly/MGGL50XVI1S

We’re at #JPM26 highlighting our growth strategy, the foundation of the new Biogen, and the potential of our growing pipeline. Hear more from our CEO and join the webcast live on January 12 at 1:30pm PT/4:30pm ET. Register here: ow.ly/2Oap50XVvqN

#News: Final data from the Phase 3 study of amyotrophic lateral sclerosis (ALS) therapy has been published in @JAMANeuro. Read more: ow.ly/eOtH50XNhrx

With @StokeTx, we’re sharing new data on an investigational therapy for Dravet syndrome at the American Epilepsy Society (AES) Annual Meeting. Join us at #AES2025 and check out details about our presentations here: ow.ly/kJGu50XCL4K

#News: With @StokeTx, we’re attending the American Epilepsy Society (AES) to share new findings in Dravet syndrome. Learn more about our presentations at #AES2025: bit.ly/4a7ziQX

#News: With Eisai, we completed a rolling submission for a Supplemental Biologics License Application (sBLA) aimed to expand options for how treatment may be administered as a starting dose for people living with early Alzheimer’s disease. Read on: ow.ly/8EKO50XxpZY